More than half of patients reduce disease severity by at least 75% Lilly IL-13 antibody phase 3 clinical results are positive

Eli Lilly and Company announced that its investigational IL-13 inhibitor, lebrikizumab, as a monotherapy, has achieved positive results in a pivotal Phase 3 clinical trial in patients with moderate-to-severe atopic dermatitis

Atopic dermatitis is a chronic inflammatory skin disease caused by skin barrier dysfunction and dysregulated immune response

Lebrikizumab is an innovative monoclonal antibody drug that binds IL-13 with high affinity and specificity, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the receptor complex-mediated signaling pathway

▲Mechanism of action of Lebrikizumab and other antibody therapies targeting IL-4 and IL-13 signaling pathways (Image source: Reference [2])

In the study, called ADvocate 1, 43% of patients treated with lebrikizumab achieved clear or almost clear skin (IGA) at 16 weeks, compared with 13% of patients treated with placebo

In the ADvocate 2 study, 33% of patients taking lebrikizumab achieved clear or almost clear skin at 16 weeks, compared with 11% of the placebo group

"Patients' experiences battling autoimmune diseases drive us at Lilly to pursue innovative science and meaningful treatments that make their lives better," said Dr.

References:

[1] Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies.

[2] Moyle et al.